Jaguar Health für Investierte und Interessierte Forum: Community User: Bsjunge
Certainly! Let’s take a look at Jaguar Health, Inc.'s performance in the previous quarters: Second Quarter 2023 (Q2 2023): Net Revenue: In Q2 2023, Jaguar Health reported a 36% increase in net revenue compared to Q1 2023. The combined net revenue for their prescription products, Mytesi® (crofelemer) and Canalevia®-CA1 (used for treating chemotherapy-induced diarrhea in dogs), was approximately $2.7 million1. Loss from Operations: The loss from operations increased by $1.6 million, from $6.4 million in Q2 2022 to $8.1 million during the same period in 2023. Clinical Trials: Jaguar Health’s paramount clinical activity is their Phase 3 pivotal OnTarget trial of Mytesi for the follow-on indication of chemotherapy-induced overactive bowel (CIOB). Top-line results from this pivotal study are expected in late October 20231. Third Quarter 2023 (Q3 2023): Net Revenue: In Q3 2023, net revenue increased by 5% compared to Q2 202323. Clinical Initiatives: Jaguar Health is also supporting investigator-initiated and investigator IND proof-of-concept studies of crofelemer for microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure in various regions. Published data from these clinical investigations could potentially support reimbursed early patient access to crofelemer for SBS or MVID, potentially in 20241. Overall, Jaguar Health continues to focus on clinical trials, revenue growth, and expanding the indications for their products. If you’re interested in more details, you can visit their official website here. 🌿📈1
Mehr zu diesem Wert
|
|
Thema | ||
|---|---|---|---|
| 1 | DAX Prognose / Germany 40 | -0,34 % | |
| 2 | DPCM Capital Hauptdiskussion | +8,68 % | |
| 3 | DAX / Germany 40 Hauptdiskussion | -0,34 % | |
| 4 | SAP Hauptdiskussion | -0,70 % | |
| 5 | Hexagon Purus Hauptdiskussion | -2,82 % | |
| 6 | Security der nächsten Generation | -1,97 % | |
| 7 | Super Micro Computer Hauptdiskussion | +3,84 % | |
| 8 | VONOVIA Hauptdiskussion | +0,49 % | |
| 9 | PLUG POWER Hauptdiskussion | +4,95 % | |
| 10 | Novo Nordisk nach Split | -1,72 % | Alle Diskussionen |
|
|
Thema | ||
|---|---|---|---|
| 1 | DPCM Capital Hauptdiskussion | +8,10 % | |
| 2 | SAP Hauptdiskussion | -0,75 % | |
| 3 | Security der nächsten Generation | -0,92 % | |
| 4 | VONOVIA Hauptdiskussion | +0,59 % | |
| 5 | Hexagon Purus Hauptdiskussion | -2,82 % | |
| 6 | Super Micro Computer Hauptdiskussion | +4,11 % | |
| 7 | PLUG POWER Hauptdiskussion | +5,28 % | |
| 8 | Novo Nordisk nach Split | -1,73 % | |
| 9 | EDGE THERAPEUTICS INC. REGISTERED SHARES DL -,00033 Hauptdiskussion | +51,85 % | |
| 10 | SERVICENOW Hauptdiskussion | -4,03 % | Alle Diskussionen |